Obsidian Therapeutics, Inc. filed an amendment to its August 3, 2026 Form 8-K to include financial statements omitted from the original report regarding the completion of a reverse merger with Galera Therapeutics, Inc. The transaction closed on July 31, 2026, following the closing of a Concurrent PIPE Financing that generated approximately $350 million in gross proceeds. Obsidian is deemed the accounting acquirer, while Galera is treated as an asset acquisition due to lacking substantive processes. Pro forma financials indicate the combined entity will have approximately $338.6 million in cash and 61.77 million shares outstanding immediately post-merger. The company operates in the clinical-stage biopharmaceutical industry, developing engineered tumor infiltrating lymphocyte (TIL) cell therapies for solid tumors.